Zobrazeno 1 - 10
of 34
pro vyhledávání: '"H. M. Earl"'
Publikováno v:
Sarcoma, Vol 4, Iss 3, Pp 129-133 (2000)
We illustrate the principle of conformal radiotherapy by discussing the case of a patient with a primitive neuroectodermal tumour of the chest wall. Recent advances in radiotherapy planning enable precise localization of the planning target volume (P
Externí odkaz:
https://doaj.org/article/78e9bdae101e426f9d162d24b10c18dc
Autor:
Helen B Higgins, Christopher J. Poole, Christopher McCabe, Victoria Harmer, Iain R. Macpherson, Jms Bartlett, Andreas Makris, SA MacIntosh, Robert Stein, D.W. Rea, Sarah E Pinder, H. M. Earl, James D. Thomas, Leila Rooshenas, Jenny L Donovan, Luke Hughes-Davies, David Cameron, Claire Hulme, Andrea Marshall, Peter Hall, Nigel Stallard, Adrienne Morgan, Bjørn Naume, Janet A. Dunn, Carmel Conefrey
Publikováno v:
Cancer Research. 79:OT1-05
Background:Multi-parameter tumour gene expression assays (MPAs) are widely used to estimate individual patient residual risk and to guide chemotherapy use in hormone-sensitive, HER2-negative early breast cancer. The TAILORx trial supports MPA use in
Autor:
Iain R. Macpherson, Jms Bartlett, Leila Rooshenas, Peter Hall, Janet A. Dunn, Robert Stein, Carmel Conefrey, Jenny L Donovan, Christopher J. Poole, Stuart McIntosh, Aideen Campbell, Andrea Marshall, Helen B Higgins, Claire Hulme, Andreas Makris, D.W. Rea, Luke Hughes-Davies, David Cameron, H. M. Earl, Sarah E Pinder, Christopher McCabe, Adrienne Morgan, Victoria Harmer, Nigel Stallard
Publikováno v:
Cancer Research. 78:OT1-06
Background: Multi-parameter gene expression assays (MPAs) are widely used to estimate individual patient residual risk in hormone-sensitive HER2-negative node-negative early breast cancer, allowing patients with low risk to safely avoid chemotherapy.
Autor:
Jane Brown, Roshan Agarwal, Catherine Harper-Wynne, A. Humphreys, Eliot Sims, Peter Hall, Mukesh Mukesh, Sundus Yahya, Nawaz Walji, Mojca Persic, Donna L. Howe, Simon Waters, Wendy Taylor, Anita Chhabra, Karen Tipples, Helen Innes, Mark Churn, Peter Ostler, Pamela Woodings, Helen Roe, Lisa H Barraclough, Shrushma Loi, Maggie Wilcox, Susan Lupton, Adrian Harnett, Rebecca Bowen, Peter Simmonds, Natasha Mithal, H. M. Earl, Apurna Jegannathen, Kathryn Wright, A.S. Dhadda, Rozenn Allerton, Jean Abraham, Karen McAdam, Ioannis Gounaris, Mohini Varughese, Mark Harries, Helen Neville-Webbe, Catherine Bale, Narottam Thanvi, Carolyn Bedi, Carlos Caldas, Fharat A. Raja, Helena M. Earl, David Miles, Trevor McGolick, Andrew D. Goodman, Kerry Raynes, Anthony Neal, Richard Simcock, Hartmut Kristeleit, Carol MacGregor, Christopher McCabe, Caroline Archer, Laura Pettit, Chris Bradley, Anne-Laure Vallier, Urmila Barthakur, Perric Crellin, S O'Reilly, Betania Mahler Araujo, Andrew Eichholz, Louise Hiller, Anne Rigg, Janine Mansi, Jacqueline Newby, Janet A. Dunn, Sarah Smith, Chris Plummer, Jennifer Marshall, Aian Moss, Zafar Malik, Larry Hayward, Mohammad Butt, Andrew M Wardley, Anup Vinayan, Shiroma De Silva-Minor, Mei-Lin Ah-See, Sue Down, Helen B Higgins, Catherine Reed, Kim Benstead, Rakesh Mehra, Luke Hughes-Davies, David Cameron, Daniel Nelmes, O.S. Din, Charlotte Moss, Daniel Epurescu, Anne C Armstrong, Nicola Storey, David J. Eaton, Hafiz Algurafi, Mariam Jafri, Daniel Rea, Nihal Shah, Elena Provenzano, Susan Cleator, Muireann Kelleher, Claire Hulme, Daniela Lee, D. Bloomfield, Margaret Daly, Joanne Cliff, Chee Goh, Sanjay Raj, Maher Hadaki, Jayant S. Vaidya, Robert Grieve
Publikováno v:
Earl, H M, Hiller, L, Vallier, A-L, Loi, S, McAdam, K, Hughes-Davies, L, Harnett, A N, Ah-See, M-L, Simcock, R, Rea, D, Raj, S, Woodings, P, Harries, M, Howe, D, Raynes, K, Higgins, H B, Wilcox, M, Plummer, C, Mansi, J, Gounaris, I, Mahler-Araujo, B, Provenzano, E, Chhabra, A, Abraham, J E, Caldas, C, Hall, P S, McCabe, C, Hulme, C, Miles, D, M Wardley, A & Cameron, D A & Dunn, J A 2019, ' 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial ', The Lancet, vol. 393, no. 10191, pp. 2599-2612 . https://doi.org/10.1016/S0140-6736(19)30650-6
Lancet (London, England)
Lancet (London, England)
Background: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd37138df2c42b14428f44dc7b4ec95b
http://wrap.warwick.ac.uk/118352/2/WRAP-6-versus-12-months-adjuvant-trastuzumab-HER2-positive-early-breast-cancer(PERSEPHONE)-Dunn-2019.pdf
http://wrap.warwick.ac.uk/118352/2/WRAP-6-versus-12-months-adjuvant-trastuzumab-HER2-positive-early-breast-cancer(PERSEPHONE)-Dunn-2019.pdf
Autor:
A Machin, Jacinta Abraham, H. M. Earl, Ellen Copson, C Harvey, S Thomas, Anne C Armstrong, Luke Hughes-Davies, L Grybowicz, Emma McMurtry, Marc Tischkowitz, Elena Provenzano, Wendi Qian, A-L Vallier, R Roylance, E Chiu, Karen McAdam
Publikováno v:
Cancer Research. 78:OT3-04
Background: No specific targeted therapies are available for Triple Negative Breast Cancers (TNBC), an aggressive and diverse subgroup. The basal TNBC subgroup show some phenotypic and molecular similarities with germline BRCA (gBRCA). In gBRCA patie
Autor:
M Weiss, H. M. Earl, Luke Hughes-Davies, Karen McAdam, A Machin, C Harvey, E McMurty, A Roberts, Elena Provenzano, Anne C Armstrong, L Grybowicz, R Roylance, Jacinta Abraham, Ellen Copson, S Thomas, Marc Tischkowitz, K Pinilla, Wendi Qian, A-L Vallier
Publikováno v:
Cancer Research. 79:OT3-03
Background: No specific targeted therapies are available for Triple Negative Breast Cancers (TNBC), an aggressive and diverse subgroup. The basal TNBC sub-group share some phenotypic and molecular similarities with germline BRCA (gBRCA) tumours. In g
Autor:
Elena Provenzano, S Thomas, Anne-Laure Vallier, M Weiss, Emma McMurtry, A Machin, Jean Abraham, K Pinilla, Karen McAdam, L Grybowicz, R Roylance, Marc Tischkowitz, Ellen Copson, Anne C Armstrong, C Harvey, Wendi Qian, Luke Hughes-Davies, A Roberts, H. M. Earl
Publikováno v:
Cancer Research. 79:OT3-01
Background: In patients with TNBC, following standard neoadjuvant chemotherapy, residual disease (RD) is correlated with poor prognosis and 50% relapse within 5 years [1]. PARTNER is a neoadjuvant clinical trial which randomises TNBC and gBRCAm patie
Autor:
Peter M. Ellis, John Yarnold, Mitchell Dowsett, Lucy Kilburn, M. Verril, Andrew M Wardley, Roger A'Hern, M Fletcher, Peter Canney, Robert E. Coleman, M McLinden, Judith M Bliss, N. Atkins, Jms Bartlett, David Cameron, H. M. Earl, Peter Barrett-Lee, D. Bloomfield
Publikováno v:
Cancer Research. 72:P1-13
Introduction: TACT, an investigator-led study in 4162 women with node positive (N+ve) or high risk node negative (N-ve) early breast cancer (EBC), is the largest taxane trial unconfounded by treatment (trt) duration. At principal analysis, with 5 yea
Autor:
H. M. Earl, Q Guo, S-F Chin, Oscar M. Rueda, C Caldas, Patricia Harrington, Paul D.P. Pharoah, Jean Abraham
Publikováno v:
Cancer Research. 72:P3-08
Background: Copy-number variations (CNVs) are DNA changes that result in regions of the genome being either duplicated (copy number gains) or deleted (copy number losses). CNVs have been identified in 12% of the human genome. Although CNVs do not app
Autor:
Susan M. Domchek, James Carmichael, Mark Wickens, Niklas Loman, Judy Garber, Andrew Tutt, Rita K. Schmutzler, Jeffrey N. Weitzel, Banu Arun, Michael Friedlander, Andrew M Wardley, M. William Audeh, H. M. Earl, Mark E. Robson, Gillian Mitchell
Publikováno v:
The Lancet. 376:245-251
Summary Background Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA -deficient cells. A maximum tolerated dose and initial signal of efficacy in BRCA -deficient ovarian cancers have be